Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

被引：65

作者：

Irving, Peter M. ^{[1
,2
,4
]}

Gecse, Krisztina B. ^{[3
]}

机构：

[1] Guys & St Thomas Hosp, Dept Gastroenterol, IBD Unit, London, England

[2] Kings Coll London, Sch Immunol & Microbial Sci, London, England

[3] Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[4] St Thomas Hosp, Dept Gastroenterol, 1st Floor,Coll House,South Wing,Westminster Bridge, London SE1 7EH, England

来源：

GASTROENTEROLOGY | 2022年 / 162卷 / 05期

基金：

英国医学研究理事会;

关键词：

Crohn's Disease; Inflammatory Bowel Diseases; Therapeutic Drug Monitoring; Ulcerative Colitis; INFLAMMATORY-BOWEL-DISEASE; INDUCTION INFLIXIMAB LEVELS; ULCERATIVE-COLITIS; COMBINATION THERAPY; TROUGH LEVELS; MAINTENANCE THERAPY; CLINICAL-RESPONSE; CROHNS-DISEASE; AZATHIOPRINE; ASSOCIATION;

D O I：

10.1053/j.gastro.2022.02.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

引用

页码：1512 / 1524

页数：13

共 100 条

[61] 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine [J].

Roblin, X ;

Serre-Debeauvais, F ;

Phelip, JM ;

Faucheron, JL ;

Hardy, G ;

Chartier, A ;

Helluwaert, F ;

Bessard, G ;

Bonaz, B .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :829-839

[62] Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial [J].

Roblin, X. ;

Boschetti, G. ;

Williet, N. ;

Nancey, S. ;

Marotte, H. ;

Berger, A. ;

Phelip, J. M. ;

Peyrin-Biroulet, L. ;

Colombel, J. F. ;

Del Tedesco, E. ;

Paul, S. ;

Flourie, B. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (02) :142-149

[63] Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial [J].

Roblin, Xavier ;

Williet, Nicolas ;

Boschetti, Gilles ;

Phelip, Jean-Marc ;

Del Tedesco, Emilie ;

Berger, Anne-Emmanuelle ;

Vedrines, Philippe ;

Duru, Gerard ;

Peyrin-Biroulet, Laurent ;

Nancey, Stephane ;

Flourie, Bernard ;

Paul, Stephane .

GUT, 2020, 69 (07) :1206-1212

[64] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease [J].

Rosario, Maria ;

French, Jonathan L. ;

Dirks, Nathanael L. ;

Sankoh, Serap ;

Parikh, Asit ;

Yang, Huyuan ;

Danese, Silvio ;

Colombel, Jean-Frederic ;

Smyth, Michael ;

Sandborn, William J. ;

Feagan, Brian G. ;

Reinisch, Walter ;

Sands, Bruce E. ;

Sans, Miguel ;

Fox, Irving .

JOURNAL OF CROHNS & COLITIS, 2017, 11 (08) :921-929

[65] Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study [J].

Samaan, Mark A. ;

Cunningham, Georgina ;

Tamilarasan, Aravind Gokul ;

Beltran, Luisa ;

Pavlidis, Polychronis ;

Ray, Shuvra ;

Mawdsley, Joel ;

Anderson, Simon H. ;

Sanderson, Jeremy D. ;

Arkir, Zehra ;

Irving, Peter M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (02) :292-302

[66] Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis [J].

Sandborn, William J. ;

Baert, Filip ;

Danese, Silvio ;

Krznaric, Zeljko ;

Kobayashi, Taku ;

Yao, Xiaopan ;

Chen, Jingjing ;

Rosario, Maria ;

Bhatia, Siddharth ;

Kisfalvi, Krisztina ;

D'Haens, Geert ;

Vermeire, Severine .

GASTROENTEROLOGY, 2020, 158 (03) :562-+

[67] Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Sands, B. E. ;

Sandborn, W. J. ;

Panaccione, R. ;

O'Brien, C. D. ;

Zhang, H. ;

Johanns, J. ;

Adedokun, O. J. ;

Li, K. ;

Peyrin-Biroulet, L. ;

Van Assche, G. ;

Danese, S. ;

Targan, S. ;

Abreu, M. T. ;

Hisamatsu, T. ;

Szapary, P. ;

Marano, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13) :1201-1214

[68] HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease [J].

Sazonovs, Aleksejs ;

Kennedy, Nicholas A. ;

Moutsianas, Loukas ;

Heap, Graham A. ;

Rice, Daniel L. ;

Reppell, Mark ;

Bewshea, Claire M. ;

Chanchlani, Neil ;

Walker, Gareth J. ;

Perry, Mandy H. ;

McDonald, Timothy J. ;

Lees, Charlie W. ;

Cummings, J. R. Fraser ;

Parkes, Miles ;

Mansfield, John C. ;

Irving, Peter M. ;

Barrett, Jeffrey C. ;

McGovern, Dermot ;

Goodhand, James R. ;

Anderson, Carl A. ;

Ahmad, Tariq .

GASTROENTEROLOGY, 2020, 158 (01) :189-199

[69] Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease [J].

Schreiber, Stefan ;

Ben-Horin, Shomron ;

Leszczyszyn, Jaroslaw ;

Dudkowiak, Robert ;

Lahat, Adi ;

Gawdis-Wojnarska, Beata ;

Pukitis, Aldis ;

Horynski, Marek ;

Farkas, Katalin ;

Kierkus, Jaroslaw ;

Kowalski, Maciej ;

Lee, Sang Joon ;

Kim, Sung Hyun ;

Suh, Jee Hye ;

Kim, Mi Rim ;

Lee, Seul Gi ;

Ye, Byong Duk ;

Reinisch, Walter .

GASTROENTEROLOGY, 2021, 160 (07) :2340-2353

[70] Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis [J].

Seow, C. H. ;

Newman, A. ;

Irwin, S. P. ;

Steinhart, A. H. ;

Silverberg, M. S. ;

Greenberg, G. R. .

GUT, 2010, 59 (01) :49-54

← 1 2 3 4 5 6 7 8 9 10 →